The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase…
Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company recently announced results from two Phase 3 trials testing AXS-05. One study, ACCORD-2, hit its…
Muna Therapeutics and GSK said they will collaborate to identify and validate new therapeutic targets for Alzheimer’s disease, a step that could pave the way for new treatments for the condition. The research collaboration will leverage Muna’s MiND-MAP platform, which analyzes analyze post-mortem brain samples from…
Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E, or amyloid-related imaging abnormalities associated with brain swelling, among adults with the neurodegenerative condition. That’s…
November is National Alzheimer’s Awareness Month, and the Alzheimer’s Foundation of America (AFA) is encouraging those impacted by Alzheimer’s disease — and their supporters — to wear teal and spread the word on social media to educate people. The AFA notes on its website that it selected…
Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials. The identified dose is unlikely to require the type of intensive drug monitoring that has been a major hurdle to the…
Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in patients with mild cognitive impairment or mild dementia. In the LIGHTWAVE study (NCT05619692), patients treated with dalzanemdor didn’t…
Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and satellite-based light pollution maps. “Average nighttime light intensity was more strongly associated with [Alzheimer’s disease] prevalence than some…
After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease. The board’s findings were announced by therapy developer…
September is awareness month for Alzheimer’s disease and other forms of dementia, and Alzheimer’s Disease International (ADI) is calling on the disease to be made a global health priority with the theme, “Time to act on dementia, time to act on Alzheimer’s.” Several initiatives have been held…
Get regular updates to your inbox.